Cerus (NASDAQ:CERS) is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.
The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products. Cerus also offers research tool products that enable academic and industrial laboratories to study pathogen inactivation mechanisms and develop further applications of its technology. These tools support investigators in exploring blood safety challenges and advancing transfusion medicine research.
Founded in 1991 and headquartered in Concord, California, Cerus has secured regulatory approvals and clearances in multiple markets, including the United States, Europe, Asia-Pacific, and Latin America. Its products are deployed by blood establishments and hospitals across more than 20 countries, where they contribute to improving patient outcomes and supporting public health initiatives.
Cerus continues to advance its pipeline with programs targeting pathogen reduction for red blood cells and novel formulations to address emerging infectious threats. The company is led by a management team with extensive experience in biotechnology, transfusion medicine, and regulatory affairs, positioning it to expand the reach of its technology and drive ongoing innovation in blood safety.
